Collections

  • Collection |

    The British Journal of Cancer publishes articles on a wide range of cancer research, including basic biology of therapeutic relevance, translational research, early- and late-phase trials, epidemiology, and precision medicine. Updated each month, our Editor's Pick showcases a curated selection of those articles which are stimulating the most interest via electronic communication and other methods. This Collection reflects the diversity, quality and relevance of the articles published in BJC. We hope you enjoy reading this Collection, and we welcome your correspondence on these studies.

    Image: JUAN GAERTNER/SCIENCE PHOTO LIBRARY; KATERYNA KON/SCIENCE PHOTO LIBRARY
  • Collection |

    Colorectal carcinoma (CRC) is a leading global cause of cancer death. Efforts to understand the drivers of CRC have uncovered several genetic determinants, but further work is needed to further elucidate its genetic aetiology, and to identify high risk individuals. Four new studies, supported by the European Cooperation in Science and Technology (COST) framework, are presented in this dedicated Collection on CRC cancer genetics. In the accompanying editorial, Luis Carvajal-Carmona (UC Davis, California) assesses their impact, and highlights the need for collaborative international research efforts to answer complex clinical questions.

    Image: JUAN GAERTNER/SCIENCE PHOTO LIBRARY; KATERYNA KON/SCIENCE PHOTO LIBRARY
  • Special |

    This Special Edition on Immunotherapy contains a selection of articles, commissioned content and videos that provide valuable insight into immunotherapy design, stratification and toxicity management.

    Image: DNA Illustrations/Science Source
  • Collection |

    On World Cancer Day , we present some of our top cited content from the last year. This selection reflects developing and ongoing trends in the cancer research community, including liquid biopsies, cancer metabolism, and our growing understanding of the immune system and immunotherapy. We hope you enjoy reading our Editor’s highlights, as we look forward to another year of exciting developments.

  • Collection |

    To mark the launch of our new Cellular and Molecular Biology section in the British Journal of Cancer, we present a series of articles to highlight our best research and reviews in this area.

    Image: Colin Goding (Ludwig Institute for Cancer Research, University of Oxford)
  • Supplement |

    In this supplement, the authors comprehensively review molecular and clinical evidence underlying the evolution of poly (ADP-ribose) polymerase (PARP) inhibitors in a journey spanning 50 years, which culminates in the recent licensing approval of the first oral PARP inhibitor, olaparib (Lynparzat™), for BRCA-mutated high-grade serous ovarian cancer.

  • Collection |

    Immunotherapies have revolutionised therapy for some cancers.In particular, antibodies that block signals that reduce inhibition of T cell function, have led to complete regressions that are maintained for years, in melanoma and now in bladder cancer and non-small cell lung cancer. Recently, chimeric antigen receptor T cells have produced remarkable responses in patients who have failed multiple other therapies. In parallel with therapeutic trials, many other mechanisms and pathways are being investigated in optimising these treatments.Many of these areas are covered in this collection of papers and reviews.

  • Focus |

    Immunotherapies against immune checkpoint inhibitors have rapidly changed treatment paradigms for several major cancers including melanoma, non-small cell lung cancer and bladder cancer. In this selection of articles we highlight the expression of one of the key pathways, PD-L1, and its potential for selecting patients for therapy.

  • Focus |

    See what scientists world-wide are reading! View the most popular minireviews published in BJC.

  • Focus |

    Exploiting and targeting the immune system are emerging as important therapeutic strategies for cancer.Here we bring together recent papers covering experimental models as well as early phase human clinical studies and highlighting novel CTL epitopes, cellular therapy approaches, cancer vaccines, and anti-tumour immunoRNases.

  • Focus |

    There are over 500 new anti-cancer drugs in various stages of clinical development. The BJC remains an important venue to report clinical trial results. The following is a brief selection of recently published trials with promising new drugs to watch.